CheckMate 8HW: nivolumab plus ipilimumab versus nivolumab alone in MSI-high metastatic colorectal cancer
Dual immunotherapy with nivolumab and ipilimumab delayed progression more than nivolumab alone across all lines of treatment in microsatellite-unstable colorectal cancer, with about seven in ten patients progression-free at three years.
Overview
Phase 3 trial of 707 patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer randomised to nivolumab plus ipilimumab, nivolumab alone or chemotherapy; this report compares the two immunotherapy arms across all lines.
Progression-free survival favoured the combination (hazard ratio 0.62; three-year rate about 68 versus 51 percent) with a higher response rate (71 versus 58 percent); grade 3 to 4 treatment-related adverse events were 22 versus 14 percent.
- Progression-free survival hazard ratio 0.62 for the combination vs nivolumab alone.
- Objective response 71 percent vs 58 percent.
Nivolumab-ipilimumab is a first-line standard for microsatellite-unstable metastatic colorectal cancer alongside pembrolizumab, with the trade-off of more immune toxicity for deeper and more durable control.
- Overall survival data immature at this report.
- The earlier comparison with chemotherapy was first line only.
Similar pages
not linked directly; found by shared links- PersonHeinz-Josef Lenz
Shares CheckMate 8HW, Mismatch-repair deficient (MSI-high) colorectal cancer, Ipilimumab, Nivolumab.
- PersonThierry André
Shares CheckMate 8HW, Mismatch-repair deficient (MSI-high) colorectal cancer, Ipilimumab, Nivolumab.
- Key paperCheckMate 743: first-line nivolumab plus ipilimumab in unresectable pleural mesothelioma
Shares The Lancet, Ipilimumab, Nivolumab.
- TrialA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Shares Ipilimumab, Nivolumab.
- Key paperNivolumab alone or with ipilimumab in mucosal melanoma: pooled analysis
Shares Ipilimumab, Nivolumab.
- TrialCheckMate 915
Shares Ipilimumab, Nivolumab.
- TrialStudy of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Shares Ipilimumab, Nivolumab.
- TrialA Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P
Shares Ipilimumab, Nivolumab.